Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer

W R Miller, M Stuart, T Sahmoud, J M Dixon

Research output: Contribution to journalArticlepeer-review

Abstract

The effect of anastrozole on peripheral and tumour aromatase activity and oestrogen levels in postmenopausal patients with oestrogen receptor-rich breast tumours was investigated. Twenty-six patients were randomly allocated to treatment with anastrozole 1 mg (n=13) or 10 mg (n=13), once daily. Before and after 12 weeks' treatment, patients were infused with 3H-Delta4 androstenedione (20 MBq) and 14C-oestrone (E1) (1 MBq) for 18 h. Oestrogens were purified from excised tumours and plasma samples taken after each infusion. Peripheral and tumour aromatase activity and tumour E1 uptake were calculated from levels of 3H and 14C in purified E1 fractions from tumour and plasma. Endogenous tumour oestrogens were measured by radioimmunoassay. Twenty-three patients were available for analysis (1 mg group, n=12; 10 mg group, n=11). Following treatment, anastrozole (1 and 10 mg) markedly inhibited peripheral aromatase in all patients (the difference between pre- and on-treatment values being highly significant P
Original languageEnglish
Pages (from-to)950-5
Number of pages6
JournalBritish Journal of Cancer
Volume87
Issue number9
DOIs
Publication statusPublished - 21 Oct 2002

Keywords

  • Aged
  • Androstenedione
  • Antineoplastic Agents, Hormonal
  • Aromatase
  • Aromatase Inhibitors
  • Breast Neoplasms
  • Double-Blind Method
  • Enzyme Inhibitors
  • Estradiol
  • Estrogen Antagonists
  • Estrogens
  • Estrone
  • Female
  • Humans
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Neoplasms, Hormone-Dependent
  • Nitriles
  • Postmenopause
  • Radioimmunoassay
  • Receptors, Estrogen
  • Triazoles

Fingerprint

Dive into the research topics of 'Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer'. Together they form a unique fingerprint.

Cite this